The FDA Category System Explained: What Category 1, 2, and 3 Mean for Your Access to Peptide Therapy

Why the FDA Category System Matters

If you have been following the peptide therapy space, you have likely encountered references to "Category 1," "Category 2," and "Category 3" substances. These designations come from the FDA's framework for regulating bulk drug substances used in compounding, and they directly determine which peptides your physician can legally prescribe through a compounding pharmacy.

Understanding these categories is not just an academic exercise. For patients who rely on compounded peptide therapies, the distinction between categories can mean the difference between continued access and a sudden loss of treatment options.

What Is the FDA Compounding Category System?

The FDA's category system was established to organize bulk drug substances — the raw active ingredients that compounding pharmacies use to prepare customized medications. This framework applies to both 503A pharmacies (traditional compounding pharmacies that fill individual prescriptions) and 503B outsourcing facilities (which can produce larger batches without patient-specific prescriptions).

The system classifies substances into three tiers based on their safety profile, regulatory history, and whether they meet established pharmaceutical standards.

Category 1: Legal for Compounding

Category 1 substances are bulk drug substances that have an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph. A USP monograph establishes identity, strength, quality, and purity standards for a substance, providing a recognized benchmark that compounding pharmacies can follow.

Substances in Category 1 are generally permitted for use in compounding by both 503A and 503B pharmacies, provided the pharmacy meets all other applicable regulatory requirements. For patients, Category 1 status means that a peptide can be legally obtained through a licensed compounding pharmacy with a valid prescription from a licensed provider.

Examples of peptides that currently hold Category 1 status include sermorelin and gonadorelin. These substances have established monographs and a longer track record in clinical compounding.

Category 2: Under Evaluation

Category 2 represents a more uncertain regulatory space. Substances placed in Category 2 are those that the FDA has identified for further evaluation. During this evaluation period, these substances are generally restricted from compounding.

The Category 2 designation does not necessarily mean a substance is unsafe. It means the FDA has not yet completed its review process to determine whether the substance should be permanently permitted or restricted. Many peptides that had been widely compounded for years were moved into Category 2 when the FDA began its more rigorous evaluation of the compounding landscape.

For patients, Category 2 status typically means that the peptide is not currently available through legal compounding channels, although this status can change based on the outcome of the FDA's review.

Category 3: Safety Concerns Identified

Category 3 is reserved for substances where the FDA has identified specific safety concerns that make them ineligible for compounding. These substances have been evaluated and determined to present risks that, in the FDA's assessment, outweigh the benefits of allowing them to be compounded.

A Category 3 designation is more definitive than Category 2. While reclassification is always theoretically possible if new evidence emerges, substances in Category 3 face a higher bar for returning to legal compounding status.

What Reclassification Means for Patients

Reclassification occurs when the FDA moves a substance from one category to another. The most relevant scenario for peptide therapy patients is the potential reclassification of substances from Category 2 to Category 1, which would restore their availability through compounding pharmacies.

When a substance is reclassified to Category 1, several things happen in sequence. First, the FDA publishes a formal notice of the reclassification. Compounding pharmacies can then begin sourcing the bulk substance from qualified suppliers. Physicians can write prescriptions, and patients can fill them at licensed compounding pharmacies.

However, reclassification does not happen overnight. Even after a formal announcement, it may take weeks or months for supply chains to stabilize and for pharmacies to begin offering the newly reclassified substance.

How to Stay Informed

The regulatory landscape for compounded peptides continues to evolve. The FDA periodically updates its lists of bulk drug substances and their category assignments. Patients and providers should monitor the FDA's Compounding Policy page and the Federal Register for formal notices of reclassification.

It is also worth noting that state pharmacy boards may impose additional restrictions beyond the federal category system. A substance that is Category 1 at the federal level may still face state-level limitations depending on your jurisdiction.

Key Considerations

The category system reflects an ongoing effort by the FDA to balance patient access with safety oversight. Regardless of where a particular peptide falls in the category framework, patients should always work with licensed healthcare providers and licensed compounding pharmacies to ensure they are receiving properly tested, quality-controlled preparations.

As regulatory developments continue through 2026, understanding these categories will be essential for anyone navigating the peptide therapy landscape.